Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-838-7
CAS number: 111-14-8
In a reproductive and developmental toxicity test (Alan, 1990), heptanoic
acid was administered orally via gavage once daily to Sprague-Dawley
virgin female rats (ten rats per group) at dosages of 0 (vehicle, corn
oil), 200, 1000 and 2000 mg/kg/day. All dosages were given at a dosage
volume of 5 ml/kg and adjusted daily for body weight changes. The rats
were observed for clinical signs, deaths and /or deliveries of litter.
Body weights were recorded daily during the dosage period and feed
consumption values were recorded periodically. All dams were necropsied
and examined for gross lesions. The litters were examined for numbers,
viability, body weights, sex ratios and external morphology of the pups.
Delivered pups were additionally examined for viability, clinical
observations and body weights during a four-day postparturition period.
The pups were necropsied when found dead.
One female and three females dead at 1000 and 2000 mg/kg/day
respectively. One high dosage group rat had urine-stained abdominal fur
and bright red, mottled lungs. During the premating and gestation
periods, rales occurred for significant numbers of rats given dosages of
200 to 2000 mg/kg/day of the test article and for significant numbers of
1000 and 2000 mg/kg/day dosage group rats during lactation. Significant
numbers of 1000 and 2000 mg/kg/day dosage group rats excess salivation
occur during the premating and gestation periods. During lactation
excess salivation occurred for significant numbers of 2000 mg/kg/day
dosage group rats. During gestation, significant numbers of 2000
mg/kg/day dose group rats had labored breathing, ungroomed coat and
decreased motor activity. The 1000 and 2000 mg/kg/day dosages of the
test article caused weight loss after the first dosage; the 2000
mg/kg/day dosage tended to cause reduced body weight gains during the
premating period. During gestation, the 2000 mg/kg/day dosage tended to
reduce maternal body weights on days 10 and 16 of gestation. The 2000
mg/kg/day dosage of the test article also tended to reduce maternal body
weight gain during lactation, and maternal body weight was significantly
reduced on day 4 postpartum, as compared with the control group value.
Absolute and relative feed consumption values tended to be reduced for
the 2000 mg/kg/day dosage group during the premating, gestation and
lactation periods. The high dosage group litters tended to have reduced
pup body weights on day 4 postpartum. No biologically relevant or
statistically significant differences occurred among the groups in the
average number of implantations, the duration of gestation, the
percentage of dams delivering one or more live pups and the pup
viability index. Administration of heptanoic acid to dams at dosages as
high as 2000 mg/kg/day did not cause malformations or gross lesions in
The maternal no-observable-adverse-effect-level (NOAEL) for heptanoic
acid was less than 200 mg/kg/day. The 200 mg/kg/day dosage of heptanoic
acid caused significant numbers of rats to have rales. The 1000 and 2000
mg/kg/day dosages caused deaths and weight losses; maternal body weight
gain and feed consumption values tended to be reduced for the 2000
mg/kg/day dosage group throughout the study, with maternal body weights
significantly reduced on days 10 and 16 of gestation and day 4 of
lactation. The NOAEL for heptanoic acid in the offspring was 1000
mg/kg/day. The 2000 mg/kg/day dosage tended to reduce pup body weight on
day 4 postpartum.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Deze website maakt gebruik van cookies om het surfen zo aangenaam mogelijk te maken.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again